The impact of the global COVID-19 pandemic on the field of rheumatology has been dramatic and broad-ranging. These effects include the pandemic’s ongoing influence on models of care delivery, the intermittent impact on drug availability to our patients, and the output of research our field has contributed to increasing our understanding of the disease’s epidemiology, basic and clinical immunology, clinical outcomes, and vaccinology in immunocompromised hosts. The next phase of the pandemic cannot be totally predicted, but there is broad agreement that SARS–CoV-2 as a global pathogen is unlikely to disappear quietly; the virus appears to be becoming endemic, and it is likely we will face continued emerging variants of unpredictable pathogenicity.

If this prediction comes to fruition, SARS–CoV-2 infections will likely impact the population along 2 different paths. The first and most common scenario will be new or recurrent infection among healthy, previously exposed, or vaccinated individuals whose disease course will, in the vast majority of cases, be of lesser severity and low mortality. The second more troubling scenario will occur with infections in our immunocompromised patients who, even if vaccinated, are more likely to experience severe outcomes from the disease (1, 2). We, as rheumatologists, must prepare for the latter scenario even though it is yet to be determined what will constitute best practice models for both prevention and care for our immunocompromised patients. There is clearly no one-size-fits-all approach, as rheumatologists practice in many different models of care, ranging from solo practices to small-and large-group practices, multispecialty, and hospitalbased practices; in each of these settings, practitioners have access to varying levels of resources. The goals, however, are the same for all of us: protecting our most vulnerable patients from infection wherever possible and contributing to providing or